Analytical Chemistry Department, Faculty of Pharmacy, Minia University, Minia, Egypt.
Luminescence. 2023 Dec;38(12):2065-2072. doi: 10.1002/bio.4597. Epub 2023 Oct 10.
The prokinetic drug, prucalopride (PCP) succinate, was determined using a new spectrofluorimetric approach with a highly sensitive, rapid, and simple procedure. The method exploited the enhancement of the inherent native fluorescence of PCP by micellar aggregation with sodium lauryl sulfate (SLS) as an anionic surfactant. Different factors that could affect the fluorescence intensity were carefully studied in order to achieve the maximal fluorescence signal. Measurement of the enhanced fluorescence was done at 354 nm after the excitation at 276 nm. The fluorescence intensity-concentration plot was rectilinear in the concentration range of 50-600 ng/ml with detection and quantitation limits of 13.9 and 42.1 ng/ml, respectively. The method underwent validation according to the International Council for Harmonisation criteria in order to assess its analytical performance, and promising results were achieved that proved the validity and reliability of the method. Furthermore, the method was employed effectively for the analysis of the cited drug in commercial pharmaceutical tablets.
促动力药物普卡必利琥珀酸酯(PCP)采用新的荧光分光光度法测定,该方法具有灵敏、快速和简单的特点。该方法利用胶束增敏作用增强 PCP 的固有本征荧光,以十二烷基硫酸钠(SLS)作为阴离子表面活性剂。为了获得最大的荧光信号,仔细研究了可能影响荧光强度的不同因素。在 276nm 激发后,在 354nm 处测量增强的荧光。荧光强度-浓度曲线在 50-600ng/ml 的浓度范围内呈线性,检测限和定量限分别为 13.9 和 42.1ng/ml。该方法根据国际协调理事会的标准进行了验证,以评估其分析性能,得到了有希望的结果,证明了该方法的有效性和可靠性。此外,该方法还有效地用于分析市售药物片中的被分析药物。